BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//XLH UK - ECPv6.15.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://xlhuk.org
X-WR-CALDESC:Events for XLH UK
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20240629T110000
DTEND;TZID=UTC:20240629T120000
DTSTAMP:20260419T122017
CREATED:20240621T041238Z
LAST-MODIFIED:20250210T114659Z
UID:29941-1719658800-1719662400@xlhuk.org
SUMMARY:Special Webinar: NICE Guidance explained
DESCRIPTION:Burosumab is a relatively new treatment\, which has been fully approved as an effective treatment for both children and adults. It is the only treatment that deals with the root cause of X-linked hypophosphataemia. \nIn people with XLH\, the hormone fibroblast growth factor 23 (FGF23) is overactive\, which signals to decrease the phosphate in the blood\, resulting in poor bone mineralisation. Burosumab (marketed as Crysvita) is a monoclonal antibody that suppresses the activity of fibroblast growth factor 23 (FGF23). By suppressing FGF23\, burosumab normalises the phosphate levels in the blood\, which helps bones and teeth to form properly. \nImplementation of NHS guidelines to make burosumab available to all UK adults is in the process of being rolled out – find out more by clicking here.
URL:https://xlhuk.org/event/special-webinar-on-nice-guidance/
LOCATION:Zoom (online meeting)
CATEGORIES:Conference and webinar,Past Events
ATTACH;FMTTYPE=image/png:https://xlhuk.org/wp-content/uploads/2024/06/500x350.png
ORGANIZER;CN="XLH UK":MAILTO:contact@xlhuk.org
END:VEVENT
END:VCALENDAR